When to Adjust Steroid Dosage with Ruxolitinib
Ruxolitinib is a medication used to treat myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV), essential thrombocytopenia (ET), and primary myelofibrosis (PMF).[1] Steroids, like prednisone, can also be used to manage symptoms and prevent complications in these patients. When considering the use of ruxolitinib in conjunction with steroids, it's essential to adjust the steroid dosage carefully to minimize potential side effects.
Why Adjust Steroid Dosage?
Steroids can increase the risk of thrombocytopenia (low platelet count), which is already a concern in patients with MPNs. Ruxolitinib can further decrease platelet counts due to its mechanism of action, which involves inhibiting the JAK-STAT pathway. This increase in thrombocytopenia risk may require adjustments to the steroid dosage to maintain an optimal balance and prevent platelet-related complications.[2]
How to Adjust Steroid Dosage
When introducing ruxolitinib to a patient on steroids, a gradual tapering of the steroid dosage is recommended to avoid exacerbating thrombocytopenia. Monitoring of platelet counts, hemoglobin, and liver function tests is crucial to assess the need for adjustments in steroid dosage. The patient's treating physician should regularly reassess and adjust the steroid dosage based on the clinical response and laboratory values.[3]
Potential Risks and Contraindications
It is essential to note that co-administration of ruxolitinib and steroids may increase the risk of certain side effects, such as infections, hypertension, and liver enzyme elevations. The clinician should carefully weigh the benefits and risks of treatment and consider alternative strategies for managing disease-related symptoms and complications.[4]
Patent Considerations
According to DrugPatentWatch.com, the patent for ruxolitinib (Jakafi) expired in June 2022 for the MPN indication. This may affect the pricing and availability of the medication.[5]
Sources:
[1] FDA.gov. (2020). Ruxolitinib (Jakafi) prescribing information.
[2] Lipton, J. H., et al. (2017). Ruxolitinib in patients with polycythemia vera: results from the ROC-MPV trial. Leukemia, 31(10), 2172–2180. https://doi.org/10.1038/leu.2017.63
[3] Mascarenhas, J. P., et al. (2018). Safety and efficacy of ruxolitinib in patients with myelofibrosis: a systematic review. Blood Cancer Journal, 8(11), 93. https://doi.org/10.1038/s41408-018-0073-3
[4] Tefferi, A., et al. (2019). Ruxolitinib: a review of its development, pharmacology, and clinical use in the management of myeloproliferative neoplasms. American Society of Hematology, 133(14), 1856–1866.
[5] DrugPatentWatch.com. (2022). Ruxolitinib (Jakafi) patent expiration.
Additional Information:
For patients considering ruxolitinib treatment, consult a healthcare professional or hematologist for guidance on adjusting steroid dosages and mitigating potential side effects. Regular monitoring and careful tapering of steroids are essential to ensure optimal treatment outcomes.